Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 7 (March 1), 2007: pp. 876-883
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.08.3311

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vonderheide, R. H.
Right arrow Articles by Antonia, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vonderheide, R. H.
Right arrow Articles by Antonia, S. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Robert H. Vonderheide, Keith T. Flaherty, Magi Khalil, Molly S. Stumacher, David L. Bajor, Natalie A. Hutnick, Patricia Sullivan, J. Joseph Mahany, Maryann Gallagher, Amy Kramer, Stephanie J. Green, Peter J. O'Dwyer, Kelli L. Running, Richard D. Huhn, Scott J. Antonia

From the Abramson Family Cancer Research Institute, Abramson Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; Thoracic Oncology Program, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL; and Pfizer Inc, New London, CT

Address reprint requests to Robert H. Vonderheide, MD, PhD, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104; e-mail: rhv{at}mail.med.upenn.edu

Purpose The cell-surface molecule CD40 activates antigen-presenting cells and enhances immune responses. CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antibody (mAb), was tested for safety in a phase I dose-escalation study.

Patients and Methods Patients with advanced solid tumors received single doses of CP-870,893 intravenously. The primary objective was to determine safety and the maximum-tolerated dose (MTD). Secondary objectives included assessment of immune modulation and tumor response.

Results Twenty-nine patients received CP-870,893 in doses from 0.01 to 0.3 mg/kg. Dose-limiting toxicity was observed in two of seven patients at the 0.3 mg/kg dose level (venous thromboembolism and grade 3 headache). MTD was estimated as 0.2 mg/kg. The most common adverse event was cytokine release syndrome (grade 1 to 2) which included chills, rigors, and fever. Transient laboratory abnormalities affecting lymphocytes, monocytes, platelets, D-dimer and liver function tests were observed 24 to 48 hours after infusion. Four patients with melanoma (14% of all patients and 27% of melanoma patients) had objective partial responses at restaging (day 43). CP-870,893 infusion resulted in transient depletion of CD19+ B cells in blood (93% depletion at the MTD for < 1 week). Among B cells remaining in blood, we found a dose-related upregulation of costimulatory molecules after treatment.

Conclusion The CD40 agonist mAb CP-870,893 was well tolerated and biologically active, and was associated with antitumor activity. Further studies of repeated doses of CP-870,893 alone and in combination with other antineoplastic agents are warranted.

Supported by Pfizer Inc, New London, CT, and by National Cancer Institute Grant No. P50 CA093372 (R.H.V.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Weiss, T. C. Back, A. J. Scarzello, J. J. Subleski, V. L. Hall, J. K. Stauffer, X. Chen, D. Micic, K. Alderson, W. J. Murphy, et al.
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
PNAS, November 17, 2009; 106(46): 19455 - 19460.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
U. K. Scarlett, J. R. Cubillos-Ruiz, Y. C. Nesbeth, D. G. Martinez, X. Engle, A. T. Gewirtz, C. L. Ahonen, and J. R. Conejo-Garcia
In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
Cancer Res., September 15, 2009; 69(18): 7329 - 7337.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. W. L. Teng, J. Sharkey, N. M. McLaughlin, M. A. Exley, and M. J. Smyth
CD1d-Based Combination Therapy Eradicates Established Tumors in Mice
J. Immunol., August 1, 2009; 183(3): 1911 - 1920.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. L. Carpenter, R. Mick, A. J. Rech, G. L. Beatty, T. A. Colligon, M. R. Rosenfeld, D. E. Kaplan, K.-M. Chang, S. M. Domchek, P. A. Kanetsky, et al.
Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
Clin. Cancer Res., July 1, 2009; 15(13): 4277 - 4287.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. W. L. Teng, S. Yue, J. Sharkey, M. A. Exley, and M. J. Smyth
CD1d Activation and Blockade: A New Antitumor Strategy
J. Immunol., March 15, 2009; 182(6): 3366 - 3371.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
C. Jackaman, A. M. Lew, Y. Zhan, J. E. Allan, B. Koloska, P. T. Graham, B. W. S. Robinson, and D. J. Nelson
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
Int. Immunol., November 1, 2008; 20(11): 1467 - 1479.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Moschonas, M. Kouraki, P. G. Knox, E. Thymiakou, D. Kardassis, and A. G. Eliopoulos
CD40 Induces Antigen Transporter and Immunoproteasome Gene Expression in Carcinomas via the Coordinated Action of NF-{kappa}B and of NF-{kappa}B-Mediated De Novo Synthesis of IRF-1
Mol. Cell. Biol., October 15, 2008; 28(20): 6208 - 6222.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. Weber
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Oncologist, October 1, 2008; 13(suppl_4): 16 - 25.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Puliaev, I. Puliaeva, L. A. Welniak, A. E. Ryan, M. Haas, W. J. Murphy, and C. S. Via
CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus
J. Immunol., July 1, 2008; 181(1): 47 - 61.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. L. Ahonen, A. Wasiuk, S. Fuse, M. J. Turk, M. S. Ernstoff, A. A. Suriawinata, J. D. Gorham, R. M. Kedl, E. J. Usherwood, and R. J. Noelle
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines
Blood, March 15, 2008; 111(6): 3116 - 3125.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al.
Toll-like Receptors in Tumor Immunotherapy
Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online